<DOC>
	<DOCNO>NCT00303940</DOCNO>
	<brief_summary>RATIONALE : Talabostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving talabostat together temozolomide carboplatin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose talabostat give together temozolomide carboplatin treat young patient relapse refractory brain tumor solid tumor .</brief_summary>
	<brief_title>Talabostat Combined With Temozolomide Carboplatin Treating Young Patients With Relapsed Refractory Brain Tumors Other Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose talabostat , use combination either temozolomide carboplatin , maximum plasma dipeptidyl peptidase IV enzyme inhibition achieve ( absence talabostat-related dose-limiting toxicity ) pediatric patient refractory relapse solid tumor , include brain tumor . - Determine maximum tolerate dose talabostat , use combination temozolomide carboplatin pediatric patient , dose-limiting toxicity attribute talabostat observe . - Define toxicity profile talabostat use combination temozolomide carboplatin . - Describe pharmacokinetic profile talabostat pediatric patient . Secondary - Study level , baseline drug administration , serum cytokine ( interleukin [ IL ] -2 , IL-6 , IL-10 , filgrastim [ G-CSF ] , tumor necrosis factor-α , IL-1β , IL-8 , IP10 , thrombospondin ) may important immune-mediated antitumor effect talabostat . - Evaluate antitumor effect talabostat combination temozolomide carboplatin pediatric solid tumor direct assessment tumor response . - Study effect talabostat neutrophil function . - Evaluate expression fibroblast activation protein ( FAP ) pediatric tumor use immunohistochemistry detect FAP paraffin-embedded tissue section exist tumor specimen , available . OUTLINE : This dose-escalation study talabostat . Patients stratify accord tumor histology prior therapy . Based stratification , patient receive either oral temozolomide day 1-5 carboplatin IV 30 minute day 1-2 . Patients also receive oral talabostat day 7-20 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . ( Closed accrual 5/25/2009 ) Cohorts 2-6 patient receive escalate dos talabostat maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 &lt; 4 12 patient experience dose-limiting toxicity first course therapy . PROJECTED ACCRUAL : A total 26 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor , include , limited , follow : Rhabdomyosarcoma soft tissue sarcomas Ewing 's sarcoma family tumor Osteosarcoma Neuroblastoma Wilms ' tumor Hepatic tumor Germ cell tumor Primary brain tumor In patient brainstem optic glioma , requirement histological confirmation waive biopsy perform Patients brainstem gliomas respond therapy without radiographic evidence disease progression must clinical evidence progression Patients brain tumor must stable taper dose corticosteroid 7 day prior study entry Measurable evaluable disease Relapsed failed respond frontline curative therapy , include follow : Surgery Radiotherapy Chemotherapy Combination modalities No potentially curative treatment option available PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8 mg/dL Platelet count ≥ 100,000/mm^3 ( platelet transfusion independent ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGPT ≤ 2.5 time ULN Creatinine clearance ≥ 60 mL/min OR ageadjusted creatinine* follow : No 0.8 mg/dL ( patient ≤ 5 year age ) No 1.0 mg/dL ( patient 6 10 year age ) No 1.2 mg/dL ( patient 11 15 year age ) No 1.5 mg/dL ( patient &gt; 15 year age ) NOTE : *For patient receive carboplatin nuclear glomerular filtration rate study , 24hour urine collection , serum creatinine estimation creatinine clearance require 15 year age OR serum creatinine weight estimation creatinine clearance require 1518 year age Patients history seizure eligible seizure control anticonvulsant No clinically significant , unrelated systemic illness , include either follow : Serious infection Hepatic , renal , organ dysfunction would preclude study treatment Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No generalize pit peripheral edema No sensitivity valineproline boronic acid PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered ≤ grade 1 acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior study entry Any number prior chemotherapy regimen allow Prior temozolomide carboplatin frontline therapy adjuvant set allow provided patient experience severe toxicity relate drug tumor progress therapy At least 3 week since last dose myelosuppressive chemotherapy At least 7 day since last dose anticancer biologic agent ( e.g. , retinoids ) At least 30 day since prior investigational agent At least 4 week since prior radiotherapy &gt; 25 % marrowcontaining bone ( pelvis , spine , skull ) ( 2 week palliative [ limitedport ] radiotherapy ) At least 2 month since prior autologous stem cell transplantation recover At least 1 week since prior filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa At least 2 week since prior pegfilgrastim No history allogeneic stem cell transplantation No concurrent anticancer chemotherapy , radiation therapy , immunotherapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent childhood malignant germ cell tumor</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood teratoma</keyword>
</DOC>